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ABSTRACT  19 
Objective 20 
To investigate associations of adherence to the Mediterranean diet (MeDi) with 21 
incidence of advanced AMD (the symptomatic form of AMD) in two European 22 
population-based prospective cohorts. 23 
Design 24 
Prospective cohorts: the Rotterdam Study I (RS-I) and the Alienor Study. 25 
Participants:  26 
4 446 participants aged ≥55 years from RS-I (The Netherlands) and 550 French adults 27 
aged 73 years or older from Alienor Study with complete ophthalmologic and dietary 28 
data were included in the present study. 29 
Methods 30 
Examinations were performed approximately every 5 years over a 21-year period (1990 31 
to 2011) in RS-I and every 2 years over a 4-year period (2006 to 2012) in Alienor Study. 32 
Adherence to the MeDi was evaluated using a 9 component score based on intake of 33 
vegetables, fruits, legumes, cereals, fish, meat, dairy products, alcohol and the 34 
monounsaturated-to-saturated fatty acids ratio. Associations of incidence of AMD with 35 
MeDi were estimated using multivariate Cox proportional Hazard models. 36 
Main outcomes measures 37 
Incidence of advanced AMD based on retinal fundus photographs. 38 
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Results 39 
Among the 4 996 included participants, 155 developed advanced incident AMD (117 40 
from RS-I and 38 from Alienor Study). The mean follow-up time was 9.9 years (range 41 
0.6 to 21.7) in RS-I and 4.1 years (range 2.5 to 5.0) in Alienor Study. 42 
Pooling data for both RS-I and Alienor study, participants with a high (6-9) MeDi score 43 
had a significantly reduced risk for incident advanced AMD compared to participants 44 
with a low (0-3) MeDi score in the fully-adjusted Cox model (HR, 0.59 [95% CI, 0.37-45 
0.95], p for trend=0.04). 46 
Conclusion 47 
Pooling data from RS-I and Alienor, higher adherence to the MeDi was associated with a 48 
41% reduced risk of incident advanced AMD. These findings support the role of a diet 49 
rich in healthful nutrient-rich foods such as fruits, vegetables, legumes and fish in the 50 
prevention of AMD.  51 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
 
INTRODUCTION 52 
Age-related macular degeneration (AMD) is the leading cause of blindness in 53 
industrialized countries1. This degenerative disease affects the central part of the retina, 54 
which is crucial for daily living tasks such as reading, driving and recognition of faces. 55 
Worldwide, 196 million people will be affected by AMD in 2020, increasing to 288 million 56 
in 20402. Advanced forms of the disease (neovascular or atrophic AMD) associated with 57 
a deep visual impairment, are generally preceded by asymptomatic early stages. While 58 
no treatment is currently available for atrophic AMD, effective treatments are available 59 
for the neovascular form3, 4. These treatments also incur major costs to society, with an 60 
estimated 2.3 billion dollars of Medicare claims in 20135. The risk of developing AMD is 61 
jointly determined by age, individual genetic background and lifestyle1, 6. Prevention 62 
strategies based on the modifiable risk factors of AMD may help decrease the major 63 
medical and social burden associated with AMD. 64 
Epidemiological studies have observed a reduced risk of AMD associated with high 65 
consumption of antioxidants (lutein and zeaxanthin7-12, fruits and vegetables rich in 66 
these nutrients), and omega-3 polyunsaturated fatty acids8,9, 13-15, provided by fish and 67 
nuts13, 14, 16, 17. However a single nutrient/food approach cannot capture the synergistic 68 
effects of food and nutrients consumed in combination in the diet. The Mediterranean 69 
diet (MeDi) is characterized by high consumption of plant foods and fish, low 70 
consumption of meat and dairy products, olive oil as the primary fat source and a 71 
moderate consumption of wine18. Adherence to the MeDi has been linked to lower rates 72 
of mortality19, chronic diseases, stroke20, cognitive decline21 and recently to diabetic 73 
retinopathy22. Regarding AMD, very few studies are available to date23-27. In three 74 
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population-based studies, it was associated with a lower prevalence of early AMD23, 75 
neovascular AMD25 and any AMD26, 27, although dietary modifications due to AMD 76 
cannot be excluded in these cross-sectional studies. In a post-hoc analysis of a 77 
randomized clinical trial, the MeDi was associated with a lower incidence of advanced 78 
AMD24, but the selected nature of the sample limits its generalizability. We therefore 79 
investigated the associations between MeDi and incidence of advanced AMD in a large 80 
sample from two population-based prospective studies.  81 
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METHODS 82 
Study population 83 
The EYE-RISK project aims at identifying risk factors, molecular mechanisms and 84 
therapeutic approaches for AMD (http://www.eyerisk.eu/). It uses epidemiological data 85 
describing clinical phenotype, molecular genetics, lifestyle, nutrition and in-depth retinal 86 
imaging derived from existing European epidemiological cohorts to provide major 87 
insights needed for prevention and therapy of AMD. Within the EYE-RISK consortium, a 88 
unique harmonized database of individual data from 16 European epidemiological 89 
studies was constructed28. Two prospective studies with appropriate data for the present 90 
analyses were available: the Rotterdam Study I29 (RS-I) and the Alienor Study30. 91 
Rotterdam Study I 92 
At baseline 7 983 eligible persons aged 55 years or older were interviewed and 93 
examined. Ophthalmological examinations and fundus photography were taken at each 94 
round starting in 1990-1993 (RS-I-1). Follow-up rounds were completed in 1993-1995 95 
(RS-I-2), 1997-1999 (RS-I-3), 2002-2004 (RS-I-4) and 2009-2011 (RS-I-5).  96 
The RS has been approved by the Medical Ethics Committee of the Erasmus MC 97 
(registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and 98 
Sport (Population Screening Act WBO, license number 1071272-159521-PG). The RS 99 
has been entered into the Netherlands National Trial Register (NTR; www.trialregister.nl) 100 
and into the WHO International Clinical Trials Registry Platform (ICTRP; 101 
www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831. 102 
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After pharmacologic mydriasis, 35° stereoscopic col or fundus photos of the macula 103 
(Topcon TRV-50VT; Topcon Optical Co., Tokyo, Japan) were taken in each of the first 3 104 
visits, and 35° digital images (Topcon TRC 50EX) we re taken for the fourth and fifth 105 
visits31. 106 
Alienor Study 107 
At baseline (2006-2008), 963 participants aged 73 years or more were interviewed and 108 
had an ophthalmological examination30. Of these, 624 and 614 were reexamined at the 109 
second (2009-2010) and third (2011-2012) visits, respectively. The design has been 110 
approved by the Ethical Committee of Bordeaux (Comité de Protection des Personnes 111 
Sud-Ouest et Outre-Mer III) in May 2006 (http://www.alienor-study.com/langue-english-112 
1.html). 113 
The eye examinations took place in the Department of Ophthalmology of the University 114 
Hospital of Bordeaux. Two 45° non-mydriatic color r etinal photographs were taken using 115 
a high-resolution digital non-mydriatic retinograph (Topcon TRC-NW6S)30. At the third 116 
visit (2011-2012), for participants who were not able to come to the hospital, the eye 117 
examination took place at home and 40° retinal phot ographs were taken using a digital 118 
non-mydriatic portable retinograph (Optomed Smartscope M5). 119 
For both studies, all participants provided written informed consent in accordance with 120 
the Declaration of Helsinki to participate in the study. 121 
 122 
 123 
 124 
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AMD classification 125 
Retinal photographs of both eyes were graded by trained graders of each study and 126 
were interpreted according to a modification of the Wisconsin Age-Related System32 for 127 
RS-I and according to the International Classification33 for Alienor. All advanced AMD 128 
cases were adjudicated and confirmed by retina specialists of the corresponding study. 129 
Phenotype harmonization was performed within the EYE-RISK Consortium28. 130 
 131 
Incidence 132 
At each visit, each subject was classified according to the worst eye into one of the 133 
following exclusive groups: no AMD, early AMD, advanced AMD. Advanced AMD was 134 
defined by the presence of neovascular or atrophic MD. 135 
Neovascular AMD included serous or hemorrhagic detachment of the retinal pigment 136 
epithelium (RPE) or sensory retina, subretinal or sub-RPE hemorrhages, and fibrous 137 
scar tissue. Geographic atrophy was defined as a discrete area of retinal 138 
depigmentation, 175 µm in diameter or larger, characterized by a sharp border and the 139 
presence of visible choroidal vessels. Early AMD (in the absence of advanced AMD) 140 
was defined by the presence of (1) soft indistinct (≥125 µm, decreasing density from the 141 
center outward and fuzzy edges) / reticular drusen only or soft distinct drusen (≥63 µm, 142 
with uniform density and sharp edges) and pigmentary abnormalities or by (2) soft 143 
indistinct large drusen (≥125 µm, decreasing density from the center outward and fuzzy 144 
edges) / reticular drusen and pigmentary abnormalities (corresponding to grades 2 and 3 145 
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of the Rotterdam Classification). No AMD was defined by the absence of early AMD and 146 
advanced AMD. 147 
Incidence of advanced AMD was defined as the subject progressing from no or early 148 
AMD at baseline to advanced AMD (either neovascular or atrophic AMD) at any time-149 
point during the study period. The date of occurrence of advanced AMD was calculated 150 
as the midpoint of the interval between the last visit without advanced AMD and the first 151 
visit with advanced AMD. Follow-up ended at the date of occurrence of advanced AMD, 152 
or the date of the last gradable photograph. Subjects with advanced AMD or no 153 
gradable eyes at baseline were excluded from the analysis. 154 
For the purpose of AMD subtype analysis, neovascular AMD comprised all subjects 155 
presenting some neovascular lesions, with or without coexisting atrophy. Atrophic AMD 156 
was defined as pure geographic atrophy (in the absence of neovascular AMD). 157 
 158 
Dietary assessment 159 
In RS-I, participants completed a checklist at home and had a face-to-face interview 160 
conducted by a trained dietitian at the research center using a 170-items validated semi-161 
quantitative food frequency questionnaire (FFQ)34. The food items were converted into 162 
quantities consumed per day (g/day). By using the computerized Dutch Food 163 
Composition Table, these dietary data were converted to total energy intake (TEI) 164 
(kcal/day) and nutrient intakes (g/day)34. 165 
In Alienor, participants were visited at home by a specifically trained dietician who 166 
administered a 40-items validated FFQ and a 24-hour dietary recall35, 36. The food items 167 
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were converted into number of servings per day. The 24-hour recall was used to 168 
estimate nutrient intake (g/day) and TEI (kcal/day) and to compute the monounsaturated 169 
fatty acids (MUFAs) to saturated fatty acids (SFAs) ratio. 170 
Adherence to the MeDi was assessed using the MeDi score developed by Trichopoulou 171 
et al37. This score including 9 components: vegetables, fruits, legumes, cereals, fish, 172 
meat, dairy products, alcohol and the MUFAs-to-SFAs ratio was applied to both studies. 173 
The daily intake of each food/beverage group was calculated as quantity in g/day in RS-I 174 
and as the number of servings/day in Alienor. Participants with unreliable TEI were 175 
excluded (valid TEI range: women: 600–3200; men: 600–4200 kcal). For each 176 
component hypothesized to benefit health (vegetables, fruits, legumes, cereals and fish, 177 
MUFAs-to-SFAs ratio), 1 point was given if intake was above the sex-specific median 178 
values and zero otherwise. For components presumed to be detrimental to health (meat 179 
and dairy products), 1 point was given if intake was below the sex-specific median 180 
values and zero otherwise. For alcohol, 1 point was given for moderate consumption 181 
and zero otherwise (moderate consumption: women: 1-10; men: 5-15 g/day). Sex-182 
specific median were calculated separately for each study. The total MeDi score was 183 
computed by adding the scores (0 or 1 point) for each component for each participant. 184 
Scores ranged from 0 (non-adherence) to 9 (perfect adherence). Subjects were 185 
classified according to 3 categories of the MeDi score: low (0–3), medium (4–5), or high 186 
(6–9). 187 
 188 
 189 
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Covariates 190 
Age (years), sex, education (primary, secondary, higher), smoking (never smoker, 191 
smoker <20 pack-years (PY), smoker ≥20 PY, PY=packs (20 cigarettes) smoked per 192 
day X years of smoking), multivitamins/minerals supplement use (Yes/No) were 193 
measured using self-reported questionnaires at baseline30 38 for each study. Vascular 194 
risk factors included body mass index (BMI: weight (kg)/height (m²)), diabetes (treated or 195 
self-reported), hypertension (blood diastolic blood pressure ≥90mmHg or systolic blood 196 
pressure ≥140mmHg or treated or self-reported), and hypercholesterolemia (treated or 197 
self-reported). Complement Factor H (CFH) Y402H (rs1061170) and Age-Related 198 
Maculopathy Susceptibly 2 (ARMS2) A69S (rs10490924), the two main AMD-related 199 
SNPs were assessed in each study39, 40. 200 
 201 
Statistical analysis 202 
Subjects excluded from analyses were compared to those included using logistic 203 
regression model adjusted for age and sex for each characteristic separately. The same 204 
method was used to compare characteristics of subjects included between the two 205 
cohorts. 206 
The associations of MeDi score with incidence of advanced AMD were analyzed using 207 
Cox proportional hazards models with delayed entry and age as a time scale, which 208 
allow for a better adjustment for age than the classical Cox models based on time from 209 
entry in the study41. Model 1 was unadjusted and model 2 was adjusted for sex, AMD 210 
grade at baseline (no or early AMD), TEI (continuous), education, BMI, smoking, 211 
multivitamins/minerals supplement use, diabetes and hypercholesterolemia. Variables 212 
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retained in model 2 were factors associated with incidence of AMD and/or with MeDi 213 
score, after adjustment for age and sex (p<0.10). For the pooled analysis, including data 214 
from both studies, models were further adjusted for the study (fixed study effect). 215 
Low MeDi score was designated as the reference group. P-trend was calculated by 216 
using the median value of the MeDi score for each category. In all Cox models, the 217 
proportional hazard assumptions were tested. 218 
Participants from RS-I and Alienor were different regarding some characteristics. To 219 
estimate the potential effect of these differences, interactions between study and each 220 
covariate were assessed and none was significant. Thus, as the proportional hazard 221 
assumptions were satisfied and there were no interactions, to account for differences 222 
between the two studies, all models combining both studies were adjusted for a fixed 223 
study effect. 224 
 225 
Secondary analyses 226 
We also assessed whether associations of MeDi score with incident advanced AMD 227 
may be due to individual dietary components by examining associations between the 228 
individual components of the MeDi score and advanced AMD. Each component was 229 
introduced independently into model 2. In secondary analyses, CFH Y402H and ARMS2 230 
A69S polymorphisms were added to model 2. Interactions between CFH Y402H and 231 
ARMS2 A69S polymorphisms and MeDi score were also analyzed. Interaction terms for 232 
the number of risk alleles and MeDi score were assessed separately for each genetic 233 
variant using model 2. All p-values representing a 2-tailed test of significance with 234 
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α=0.05 and SAS version 9.4 (SAS Institute Inc. Cary, NC, USA) was used for all 235 
analyses.  236 
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RESULTS 237 
Of the 7 146 participants at risk of developing advanced AMD, 1 337 had no follow-up 238 
data for both eyes. In addition, 813 were excluded due to missing/unreliable dietary data 239 
(Figure 1). Overall 4 996 (4 446 from RS-I and 550 from Alienor) participants free from 240 
advanced AMD at baseline with complete and reliable dietary data together with follow-241 
up information were included in our analyses. 242 
Among the 4 996 included participants, 155 developed advanced incident AMD (117 243 
from RS-I and 38 from Alienor). The mean follow-up time was 9.9 years (range 0.6 to 244 
21.7) in RS-I and 4.1 years (range 2.5 to 5.0) in Alienor. 245 
In both studies, participants included in the analyses tended to be younger than those 246 
excluded (Table 1). In RS-I, after adjustment for age and sex, included participants 247 
tended to be more women, to have a higher education, to have a history of smoking and 248 
diabetes, a lower TEI, a higher MeDi score and to carry less often a CFH Y402H CC 249 
genotype than excluded participants. In Alienor, included participants were more likely to 250 
have a higher education, than excluded participants. 251 
Participants from RS-I, tended to be younger, to have a lower education, to have a 252 
history of smoking, to have less hypertension and less hypercholesterolemia as well as 253 
a higher TEI, a lower adherence to the MeDi score and to have less early AMD than 254 
participants from Alienor. Also CFH Y402H polymorphism was slightly different between 255 
the two studies.  256 
Participants from Alienor tented to have a higher median of consumption of vegetables, 257 
cereals and fish, whereas subjects from RS-I tented to have a higher median of 258 
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consumption of dairy products. Consumption of fruits, legumes, meat and the MUFAs-to-259 
SFAs ratio were similar (eTable 1). 260 
For both studies, the incidence of advanced AMD was lower among subjects who had a 261 
high adherence to the MeDi score (Figure 2). The effect of MeDi is more noticeable 262 
among older people (85+), at higher risk of AMD, but as the proportional hazard 263 
assumption is respected, associations are considered similar among the different age 264 
groups. 265 
In the unadjusted model, similar estimations were obtained in both studies, with a HR of 266 
0.56 [95% CI 0.33 to 0.96] in RS-I and 0.48 [95% CI 0.18 to 1.26] in Alienor for 267 
participants with a high MeDi score, by comparison with a low MeDi score (Table 2). 268 
When pooling both studies, a high MeDi score was significantly associated with a lower 269 
risk for incident advanced AMD (HR, 0.53 [95% CI, 0.33-0.84], p-trend=0.009). These 270 
associations remained similar and significant after further adjustment for sex, TEI, AMD 271 
grade at baseline, education, BMI, smoking, supplement use of multivitamins/minerals, 272 
diabetes and hypercholesterolemia, (HR, 0.59 [95%CI, 0.37-0.95], p-trend=0.04). 273 
In secondary analyses, we further adjusted for CFH Y402H and ARMS2 genes and the 274 
HR remained unchanged (data not shown). 275 
Interactions terms between MeDi and CFH Y402H and ARMS2 genes were not 276 
statistically significant (p for interaction=0.89 and 0.18, respectively, data not shown). 277 
Adherence to MeDi score was not significantly associated with the risk for incident 278 
neovascular AMD neither in RS-I nor in Alienor or in the pooled analysis (Table 3). It 279 
was significantly associated with the risk for incident atrophic AMD in RS-I (HR=0.41, p-280 
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trend=0.046) but the association did not reach significance in Alienor (HR=0.52, p-281 
trend=0.52). In the pooled data analysis, a higher MeDi score was significantly 282 
associated with a reduced risk for incident atrophic AMD (HR, 0.42 [95%CI, 0.20-0.90], 283 
p-trend=0.04). 284 
We assessed whether the benefit of high adherence to the MeDi score was due to a 285 
specific component. Using the sex-specific median as cutoffs, no component was 286 
significantly associated with incidence of advanced AMD (eTable 2).  287 
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DISCUSSION 288 
High adherence to the MeDi was associated with a 41% reduced risk of incident 289 
advanced AMD in the pooled analysis. None of the nine components, including 290 
vegetables, fruits, legumes, cereals, fish, the MUFAs-to-SFAs ratio, meat, dairy products 291 
and alcohol consumption, was significantly associated with incidence of advanced AMD, 292 
highlighting the importance of assessing dietary patterns rather than single components. 293 
In our studies, a high adherence to the MeDi was significantly associated with a reduced 294 
risk of incident atrophic AMD. A similar association was observed for neovascular AMD 295 
but did not reach statistical significance. 296 
By evaluating the individual and the pooled associations of the adherence to the MeDi 297 
and incidence of advanced AMD in two well established and harmonized European 298 
population-based prospective cohorts, this study expands on prior studies, mainly cross-299 
sectional, case-control, and clinical trials on this topic. Visual impairment due to AMD 300 
could influence dietary practices; prospective studies, by assessing diet prior the onset 301 
of the disease, limits reverse causation. Thus, prospective design is more accurate and 302 
less biased than a cross-sectional or case-control design to evaluate the association 303 
between diet and AMD. In addition, although using a prospective design, clinical trials 304 
are limited by the selected nature of the sample. Results from population-based studies 305 
are more generalizable. 306 
Our results are partially consistent with previous cross-sectional studies: the CAREDS 307 
study reported a lower prevalence of early AMD in American women with high 308 
adherence to the MeDi23, the Coimbra Study demonstrated a lower prevalence of any 309 
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AMD in Portuguese participants who were having a high adherence to the MeDi26, 27 and 310 
the European Eye Study (Eureye) showed a lower prevalence of neovascular AMD in 311 
subjects with a high MeDi score while atrophic AMD was not associated with MeDi 312 
score25. Our findings confirm the post-hoc analyses of the AREDS clinical trial. In this 313 
sample of American participants aged 55 to 80 years, a high MeDi score was associated 314 
with a 26% lower risk of progression to advanced AMD24. The AREDS study also 315 
showed that fish and vegetable components were associated with a lower risk of 316 
progression to advanced AMD24. Our results were in the same direction but did not 317 
reach the statistical significance when sex-specific median cutoffs were used. No 318 
significant interactions were observed between MeDi score and CFH Y402H and 319 
ARMS2 genes. Our findings report a significant association with advance AMD. 320 
Regarding subtypes, only atrophic AMD was significantly associated with MeDi score. 321 
For neovascular AMD even if the association was not statistically significant, the HRs 322 
were similar to those for atrophic AMD. These differences could be explained by a low 323 
number of incident cases. In the Eureye Study, the only study to show separate results 324 
for the two advanced forms of AMD, association was significant with neovascular AMD. 325 
While in our studies this association with neovascular AMD was not statistically 326 
significant, HRs were similar to those for Eureye study. 327 
Our results thus support public health efforts to emphasize adherence to the MeDi for 328 
everyone. The biological basis for the potential benefits of the MeDi is associated with a 329 
decrease in oxidative stress and inflammation, which are also involved in the 330 
pathophysiology of AMD42, 43. 331 
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The PREDIMED study, a clinical trial among persons at high cardiovascular risk, 332 
showed that adhering to a MeDi reduced the incidence of major cardiovascular events20. 333 
Median consumptions were similar to the goals suggested by PREDIMED for vegetables 334 
(≥2 serving/d), fish (≥3 serving/w) and meat (<1 serving/d) in Alienor and for meat in RS-335 
-I. For both studies, median of fruits and legumes were below the goals of PREDIMED 336 
(≤3 serving/d) as well as median of vegetables, and fish in RS-I. Even though the 337 
medians in our study were lower for vegetables and fruits, the association with the MeDi 338 
score was significant, suggesting the importance of a global approach to prevent the 339 
development of AMD. 340 
By showing a prospective association between AMD and MeDi, an energy-unrestricted 341 
diet mainly composed of nutrient-rich food, our study confirms the importance of dietary 342 
quality focused on healthful foods and dietary patterns rather than single nutrients or 343 
low-energy diet for AMD. 344 
In observational studies, residual confounding is always a concern. In the present study, 345 
results were similar in the basic model (unadjusted model) and the fully-adjusted model 346 
(adjusted for sex, TEI, AMD grade at baseline, cardiovascular risk factors, educational 347 
level and dietary supplement use), suggesting that our results are not highly 348 
confounded. In the fully-adjusted model, association between MeDi and incidence of 349 
AMD seems to be weaker in RS-I. This could be explained by a lower statistical power 350 
due to a low incidence of participants developing advanced AMD combined to the 351 
increasing number of covariates compared to the unadjusted model. In addition, our 352 
findings are based on prospective follow-up, thereby limiting reverse causation. 353 
However, only randomized clinical trials can prove the causal nature of the associations. 354 
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Such randomized clinical trials testing dietary interventions have proven to be efficient in 355 
the prevention of stroke20 or diabetes44, for instance, but none are available in the field 356 
of AMD. 357 
Selection bias cannot be completely dismissed, as participants included in this analysis 358 
were different from non-participants in both RS-I and Alienor. Moreover, participants 359 
included from RS-I were different from those from Alienor regarding some 360 
sociodemographic and medical characteristics as well as follow-up time duration and 361 
frequency.  Incidence rates of AMD were also higher in Alienor than in RS-I. These 362 
differences might be explained by the older age at baseline and a closer follow-up (every 363 
2 years instead of 5 years in RS-I, with home examinations for participants unable to 364 
come to the hospital in Alienor but not in every RS-I follow-up visit), or by different 365 
incidence rates in France and the Netherlands. 366 
The MeDi score uses cutoffs based on each study population and results can only be 367 
generalizable to similar populations. To calculate the MeDi score, we used validated 368 
FFQs for both studies, adapted to the specific dietary habits of each population (France 369 
and the Netherlands). As the FFQ in Alienor was a 40-items FFQ, we used the 24h 370 
recall to calculate the MUFAs-to-SFAs ratio and the TEI to increase the exactitude of 371 
their ascertainment, as previously published21. The distribution of the MeDi score was 372 
different between the two studies, participants from RS-I were less adherent. This result 373 
was expected in a North European population.  374 
Despite these major differences in populations (different countries, different time 375 
periods, different generations and different diet habits) and methods (different follow-up 376 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
 
time and frequency, different dietary assessment methods), the association between 377 
MeDi and incidence of advanced AMD was similar in both cohorts. This association thus 378 
appears to be robust. 379 
To strengthen our analyses, we excluded subjects with unusually high or low TEI and 380 
adjusted for several factors know to be related to MeDi and AMD. We used a well-known 381 
and validated score to assess diet and probable synergistic effects between nutrients 382 
and food groups. Our MeDi score was developed by using sex-specific thresholds 383 
according to each study to better account for differences between men and women and 384 
studies. Other strengths include a large sample from two well documented and data-385 
harmonized population-based prospective cohorts in the framework of the European 386 
EYE-RISK project. 387 
In conclusion, combined results from our two observational studies suggest that 388 
adopting an energy-unrestricted diet rich in healthful nutrient-rich foods such as fruits, 389 
vegetables, legumes and fish, and, reducing the unhealthful foods such as red and 390 
processed meats, savory and salty industrialized products may contribute to the 391 
prevention of AMD.392 
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Figure 1. Selection of participants for analyses.  542 
Figure 2. Incidence of advanced AMD according to adherence to Mediterranean Diet 543 
(MeDi) score. 544 
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Table 1. Baseline characteristics of the Rotterdam Study I (RS-I) and the Alienor Study, 
according to participants included and excluded from analyses.  
Characteristics Rotterdam Study I Alienor Study  
 
Includeda 
(n=4 446) 
Excludedb 
(n=1 867) 
P 
valuec 
Includeda 
(n=550) 
Excludedb 
(n=283) 
P 
valuec 
P valuec RS-I 
vs Alienor 
for included 
subjects 
 No. (%)  No. (%)   
Age, mean (SD), y        
 66.9 (7.3) 73.4 (10.0) <0.0001 79.2 (4.2) 81.1 (4.3) <0.0001 <0.0001 
Sex   0.006   0.61 0.08 
Men 1813 (40.8) 766 (41.0)  209 (38.0) 108 (38.2)   
Women 2633 (59.2) 1101 (59.0)  341 (62.0) 175 (61.8)   
Education  N=4426 N=1808 <0.0001  N=283 0.03 <0.0001 
Primary 2200 (49.7) 1151 (63.6)  301 (54.7) 180 (63.6)   
Secondary 1823 (41.2) 529 (29.3)  130 (23.7) 56 (19.8)   
Higher 403 (9.1) 128 (7.1)  119 (21.6) 47 (16.6)   
Smoking, pack-years N=4131 N=1644 0.009 N=547 N=278 0.77 <0.0001 
Never smoker 1501 (36.3) 667 (40.6)  356 (65.1) 179 (64.4)   
<20 1173 (28.4) 413 (25.1)  95 (17.4) 51 (18.3)   
≥20 1457 (35.3) 564 (34.3)  96 (17.5) 48 (17.3)   
Multivitamin/mineral 
supplement use N=4442 N=1867 0.11  N=281 0.32 
0.05 
No 4070 (91.7) 1660 (88.9)  475 (86.4) 237 (84.3)   
Yes 370 (8.3) 207 (11.1)  75 (13.6) 44 (16.7)   
Body mass index, mean 
(SD), kg/m² 
N=4426 N=1775 0.26 N=542 N=274 0.87 0.17 
 26.3 (3.6) 26.2 (4.0)  26.0 (4.0) 25.9 (4.1)   
Diabetes  N=4444  0.003  N=281 0.33 0.63 
No 3941 (88.7) 1693 (90.7)  489 (88.9) 243 (86.5)   
Yes 503 (11.3) 174 (9.3)  61 (11.1) 38 (13.5)   
Hypertension    0.28  N=281 0.48 <0.0001 
No 1883 (42.3) 593 (31.8)  86 (15.6) 46 (16.4)   
Yes 2563 (57.7) 1274 (68.2)  464 (84.4) 235 (83.6)   
Hypercholesterolemia  N=4442  0.18  N=281 0.76 <0.0001 
No 4317 (97.2) 1837 (98.4)  275 (50.0) 146 (52.0)   
Yes 125 (2.8) 30 (1.6)  275 (50.0) 135 (48.0)   
CFH (rs1061170) N=3972 N=1581 0.02 N=450 N=235 0.81 0.03 
TT 1649 (41.5) 632 (40.0)  212 (47.1) 101 (43.0)   
CT 1801 (45.3) 709 (44.8)  181 (40.2) 110 (46.8)   
CC 522 (13.2) 240 (15.2)  57 (12.7) 24 (10.2)   
ARMS2 (rs10490924) N=3971 N=1582 0.16 N=450 N=235 0.12 0.11 
GG 2490 (62.7) 1028 (65.0)  309 (68.7) 145 (61.7)   
GT 1339 (33.7) 500 (31.6)  126 (28.0) 85 (36.2)   
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TT 142 (3.6) 54 (3.4)  15 (3.3) 5 (2.1)   
Total energy intake, mean 
(SD), kcal 
 N=687 0.0002  N=242 0.90 <0.0001 
 1968 (484) 2016 (609)  1719 
(530) 
1704 (549)   
Mediterranean Diet score  N=398 0.04d  N=209 0.70d <0.0001d 
Low 0-3 1376 (31.0) 153 (38.4)  171 (31.1) 58 (27.8)   
Medium 4-5 2123 (47.7) 181 (45.5)  236 (42.9) 100 (47.8)   
High 6-9 947 (21.3) 64 (16.1)  143 (26.0) 51 (24.4)   
AMD grade at baseline   0.11   0.05 0.001 
No AMD 4179 (94.0) 1654 (88.6)  444 (80.7) 241 (85.2)   
Early AMD 267 (6.0) 213 (11.4)  106 (19.3) 42 (14.8)   
a Participants included in one or more analyses for incidence of advanced AMD 
b Participants excluded from all analyses 
c p value from logistic regression adjusted for age and sex 
d p value from logistic regression adjusted for age, sex and total energy intake 
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Table 2. Association between Mediterranean Diet (MeDi) score and incidence of advanced age-
related macular degeneration (AMD). 
 
  Mediterranean Diet Score  
 
No. at 
risk for 
advance
d AMD 
No. 
incident 
cases 
Low 0-3 Medium 4-5 High 6-9 P for trenda 
Model 1b       
Rotterdam I 4446 117     
HR (95% CI)c   Reference  0.69 (0.46-1.03) 0.56 (0.33-0.96) 0.036 
Alienor 550 38     
HR (95% CI)c   Reference 0.80  (0.39-1.63) 0.48 (0.18-1.26) 0.16 
Overall 4996 155     
HR (95% CI)d   Reference 0.71 (0.50-1.00) 0.53 (0.33-0.84) 0.009 
Model 2e       
Rotterdam I 4104 108     
HR (95% CI)c   Reference 0.70 (0.46-1.06) 0.69 (0.40-1.20) 0.19 
Alienor 539 38     
HR (95% CI)c   Reference 0.83 (0.38-1.80) 0.52 (0.19-1.40) 0.23 
Overall 4643 146     
HR (95% CI)d   Reference 0.70 (0.49-1.01) 0.59 (0.37-0.95) 0.04 
a
 p for trend is calculated using the median value for each Mediterranean Diet score category. 
b Model 1, unadjusted model. 
c
 estimated using Cox proportional hazard model. 
d
 estimated using Cox proportional hazard model with additional adjustment for study. 
e Model 2, adjusted for sex, total energy intake, AMD grade at baseline, education, body mass 
index, smoking, supplement use of multivitamins/minerals, presence of diabetes and 
hypercholesterolemia. 
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Table 3. Association between Mediterranean Diet score (MeDi) and incidence of advanced 
neovascular and atrophic age-related macular degeneration (AMD). 
   Mediterranean Diet Score categories  
 
No. at risk 
for 
advanced 
AMD 
No. 
incident 
cases 
Low 0-3 Medium 4-5 High 6-9 P for trenda 
Neovascular AMD 
      
Rotterdam I 4104 68     
HR (95% CI)b   Reference 0.87 (0.51-1.51) 1.03 (0.53-1.99) 0.91 
Alienor 538 18     
HR (95% CI)b   Reference 0.80 (0.25-2.63) 0.75 (0.20-2.91) 0.65 
Overall 4642 86     
HR (95% CI)c   Reference 0.78 (0.48-1.27) 0.88 (0.49-1.57) 0.64 
Atrophic AMD 
      
Rotterdam I 4104 52     
HR (95% CI)b   Reference 0.61 (0.34-1.10) 0.41 (0.16-1.03) 0.046 
Alienor 538 21     
HR (95% CI)b   Reference 1.08 (0.38-3.06) 0.52 (0.13-2.12) 0.52 
Overall 4642 73     
HR (95% CI)c   Reference 0.70 (0.42-1.15) 0.42 (0.20-0.90) 0.04 
a
 p for trend is calculated using the median value for each MeDi score category. 
b Cox proportional hazard model adjusted for sex, total energy intake, AMD grade at baseline, 
education, body mass index, smoking, supplement use of multivitamins/minerals, diabetes and 
hypercholesterolemia. 
c
 Cox proportional hazard adjusted for sex, total energy intake, AMD grade at baseline, study, 
education, body mass index, smoking, supplement use of multivitamins/minerals, diabetes and 
hypercholesterolemia. 
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Highlights 
We examined the association of the Mediterranean diet with incident AMD in two 
European population-based prospective cohorts. A higher adherence to the 
Mediterranean diet was associated with a reduced risk of developing advanced AMD. 
